Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals A multicenter study

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMACHADO, Soraia M.
dc.contributor.authorVIGANI, Aline G.
dc.contributor.authorLEITE, Andrea G.
dc.contributor.authorDIAZ, Ana Claudia M.
dc.contributor.authorFERREIRA, Paulo Roberto A.
dc.contributor.authorCARNAUBA-JUNIOR, Dimas
dc.contributor.authorTENORE, Simone B.
dc.contributor.authorBRANDAO-MELLO, Carlos Eduardo
dc.contributor.authorGONZALEZ, Mario P.
dc.contributor.authorSIROMA, Fabiana
dc.contributor.authorPRADO, Kleber D.
dc.contributor.authorV, Delzi Nunes
dc.contributor.authorLISBOA-NETO, Gaspar
dc.contributor.authorPINHO, Joao Renato R.
dc.contributor.authorMALTA, Fernanda M.
dc.contributor.authorAZEVEDO, Raymundo S.
dc.contributor.authorWITKIN, Steven S.
dc.contributor.authorMENDES-CORREA, Maria Cassia
dc.date.accessioned2020-10-15T14:38:38Z
dc.date.available2020-10-15T14:38:38Z
dc.date.issued2020
dc.description.abstractIn a hepatitis C virus (HCV)/HIV-positive Brazilian cohort, evaluate the safety and efficacy of HCV DAAs, the frequency of resistance substitutions in the HCV NS5A and NS5B genes and identify predictors of treatment failure. Retrospective multicenter study of HCV/HIV patients treated with sofosbuvir (SOF)-based regimens at 10 reference centers in Brazil. Clinical and virological data were collected. Genetic diversity in the NS5A and NS5B genes was assessed by direct nucleotide sequencing. The primary outcome was sustained virological response (SVR) 12 weeks after DAA completion. Of 643 HCV/HIV patients analyzed, 74.7% were male, median CD4+ T cell count was 617 cells/mm(3), 90% had an undetectable HIV viral load. HCV genotype 1 was detected in 80.2%, and 60% were taking at least 1 medication other than antiretroviral drugs during their DAA therapy. Cirrhosis was present in 42%. An SOF/daclatasvir (DCV) regimen was used in most patients (98%). The frequency of NS5A polymorphisms associated with clinically relevant resistance to DCV was 2%; no relevant NS5B variants were identified. The SVR12 rate was 92.8% in an intention to treat (ITT) analysis and 96% in a modified ITT (m-ITT) analysis. AE occurred in 1.6% of patients. By multivariate analysis, therapeutic failure was associated, in the m-ITT analysis, with concomitant use of anticonvulsant drugs (P = .001), age (P = .04), and female gender (P = .04). SOF/DCV regimens were associated with a high SVR rate in an HCV/HIV population. The use of concurrent anticonvulsant drugs and DAAs decreases the chances of achieving an SVR.eng
dc.description.indexMEDLINEeng
dc.identifier.citationMEDICINE, v.99, n.30, article ID 21270, 8p, 2020
dc.identifier.doi10.1097/MD.0000000000021270
dc.identifier.eissn1536-5964
dc.identifier.issn0025-7974
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/37890
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofMedicine
dc.rightsopenAccesseng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.subjectdirect acting antiviralseng
dc.subjecteffectivenesseng
dc.subjecthepatitis C treatmenteng
dc.subjecthepatitis C-HIV coinfectioneng
dc.subjectsafetyeng
dc.subject.otherdaclatasvir plus sofosbuvireng
dc.subject.otheradvanced liver-diseaseeng
dc.subject.otherhiv-hcv coinfectioneng
dc.subject.otherreal-lifeeng
dc.subject.othergenotype 3eng
dc.subject.othernatural-historyeng
dc.subject.otherribavirineng
dc.subject.otherfibrosiseng
dc.subject.otherregimenseng
dc.subject.othertherapyeng
dc.subject.wosMedicine, General & Internaleng
dc.titleEffectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals A multicenter studyeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalVIGANI, Aline G.:Univ Estadual Campinas, Campinas, SP, Brazil
hcfmusp.author.externalLEITE, Andrea G.:Ctr Specialized Hlth, Caxias Do Sul, RS, Brazil
hcfmusp.author.externalDIAZ, Ana Claudia M.:Infect Dis Outpatient Clin, Jundiai, Brazil
hcfmusp.author.externalFERREIRA, Paulo Roberto A.:Univ Fed Sao Paulo, Infect Dis Dept, Sao Paulo, Brazil
hcfmusp.author.externalCARNAUBA-JUNIOR, Dimas:Ctr Referencia & Treinamento CRT DST AIDS, Sao Paulo, Brazil
hcfmusp.author.externalTENORE, Simone B.:Ctr Referencia & Treinamento CRT DST AIDS, Sao Paulo, Brazil
hcfmusp.author.externalBRANDAO-MELLO, Carlos Eduardo:Fed Univ State Rio de Janeiro, Rio De Janeiro, Brazil
hcfmusp.author.externalGONZALEZ, Mario P.:Emilio Ribas Hosp, Sao Paulo, Brazil
hcfmusp.author.externalSIROMA, Fabiana:Emilio Ribas Hosp, Sao Paulo, Brazil
hcfmusp.author.externalPRADO, Kleber D.:Heliopolis Hosp, Sao Paulo, Brazil
hcfmusp.author.externalV, Delzi Nunes:Base Hosp Funfarme, Sao Jose Do Rio Preto, Brazil
hcfmusp.author.externalLISBOA-NETO, Gaspar:Univ Sao Paulo, Sch Med, Sao Paulo, Brazil
hcfmusp.citation.scopus7
hcfmusp.contributor.author-fmusphcSORAIA MAFRA MACHADO
hcfmusp.contributor.author-fmusphcJOAO RENATO REBELLO PINHO
hcfmusp.contributor.author-fmusphcFERNANDA DE MELLO MALTA
hcfmusp.contributor.author-fmusphcRAYMUNDO SOARES DE AZEVEDO NETO
hcfmusp.contributor.author-fmusphcSTEVEN SOL WITKIN
hcfmusp.contributor.author-fmusphcMARIA CASSIA JACINTHO MENDES CORREA
hcfmusp.description.articlenumber21270
hcfmusp.description.issue30
hcfmusp.description.volume99
hcfmusp.origemWOS
hcfmusp.origem.pubmed32791706
hcfmusp.origem.scopus2-s2.0-85089530889
hcfmusp.origem.wosWOS:000558420900052
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAlter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004eng
hcfmusp.relation.reference[Anonymous], 2016, GLOB AIDS UPDeng
hcfmusp.relation.referenceArias A, 2017, ANTIVIR THER, V22, P307, DOI 10.3851/IMP3061eng
hcfmusp.relation.referenceBarreiro P, 2014, ANTIVIR RES, V105, P1, DOI 10.1016/j.antiviral.2014.02.004eng
hcfmusp.relation.referenceBedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201eng
hcfmusp.relation.referenceBeisel C, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-16eng
hcfmusp.relation.referenceBerenguer J, 2018, HEPATOLOGY, V68, P32, DOI 10.1002/hep.29814eng
hcfmusp.relation.referenceBhattacharya D, 2017, CLIN INFECT DIS, V64, P1711, DOI 10.1093/cid/cix111eng
hcfmusp.relation.referenceBischoff J, 2018, HIV MED, V19, P299, DOI 10.1111/hiv.12579eng
hcfmusp.relation.referenceBoesecke C, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx158eng
hcfmusp.relation.referenceBonora S, 2017, AIDS REV, V19, P24eng
hcfmusp.relation.referenceBourliere M, 2012, ANTIVIR THER, V17, P101, DOI 10.3851/IMP1935eng
hcfmusp.relation.referenceBrasil, 2015, PROT CLIN DIR TER HEeng
hcfmusp.relation.referenceCachay E, 2018, 25 C RETR OPP INF CReng
hcfmusp.relation.referenceCachay E, 2016, AIDS, V30, P2000, DOI 10.1097/QAD.0000000000001135eng
hcfmusp.relation.referenceCastera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018eng
hcfmusp.relation.referenceCaudai C, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2017.08.003eng
hcfmusp.relation.referenceChen ZW, 2016, SCI REP, V6, P203eng
hcfmusp.relation.referenceChou R, 2013, ANN INTERN MED, V158, P807, DOI 10.7326/0003-4819-158-11-201306040-00005eng
hcfmusp.relation.referenceCollins LF, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofx264eng
hcfmusp.relation.referenceCollins LF, 2017, OPEN FORUM INFECT DI, V5eng
hcfmusp.relation.referenceCosta VD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216327eng
hcfmusp.relation.referenceEuropean Ass Study Liver, 2017, J HEPATOL, V66, P153, DOI 10.1016/j.jhep.2016.09.001eng
hcfmusp.relation.referenceFried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047eng
hcfmusp.relation.referenceFuller BE, 2009, CURR OPIN PSYCHIATR, V22, P401, DOI 10.1097/YCO.0b013e32832cadb9eng
hcfmusp.relation.referenceGarimella T, 2016, ADV THER, V33, P1867, DOI 10.1007/s12325-016-0407-5eng
hcfmusp.relation.referenceGjaerde LI, 2016, CLIN INFECT DIS, V63, P821, DOI 10.1093/cid/ciw380eng
hcfmusp.relation.referenceGoulet JL, 2005, AIDS, V19, pS99, DOI 10.1097/01.aids.0000192077.11067.e5eng
hcfmusp.relation.referenceHernandez D, 2013, J CLIN VIROL, V57, P13, DOI 10.1016/j.jcv.2012.12.020eng
hcfmusp.relation.referenceIngiliz P, 2015, CURR OPIN HIV AIDS, V10, P303, DOI 10.1097/COH.0000000000000187eng
hcfmusp.relation.referenceKalaghatgi P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155869eng
hcfmusp.relation.referenceLacombe K, 2017, JAIDS-J ACQ IMM DEF, V75, P97, DOI 10.1097/qai.0000000000001342eng
hcfmusp.relation.referenceLeroy V, 2016, HEPATOLOGY, V63, P1430, DOI 10.1002/hep.28473eng
hcfmusp.relation.referenceLi GD, 2017, ANTIVIR RES, V142, P83, DOI 10.1016/j.antiviral.2017.02.014eng
hcfmusp.relation.referenceLontok E, 2015, HEPATOLOGY, V62, P1623, DOI 10.1002/hep.27934eng
hcfmusp.relation.referenceLuetkemeyer AF, 2016, CLIN INFECT DIS, V62, P1489, DOI 10.1093/cid/ciw163eng
hcfmusp.relation.referenceMalta F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2817-7eng
hcfmusp.relation.referenceMandorfer M, 2016, AIDS, V30, P1039, DOI 10.1097/QAD.0000000000001020eng
hcfmusp.relation.referenceMilazzo L, 2017, HIV MED, V18, P284, DOI 10.1111/hiv.12429eng
hcfmusp.relation.referenceMiotto N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199941eng
hcfmusp.relation.referenceNagaty A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184654eng
hcfmusp.relation.referenceNelson DR, 2015, HEPATOLOGY, V61, P1127, DOI 10.1002/hep.27726eng
hcfmusp.relation.referenceNeukam K, 2017, HIV CLIN TRIALS, V18, P126, DOI 10.1080/15284336.2017.1330801eng
hcfmusp.relation.referencePlatt L, 2016, LANCET INFECT DIS, V16, P797, DOI 10.1016/S1473-3099(15)00485-5eng
hcfmusp.relation.referenceRockstroh JK, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx154eng
hcfmusp.relation.referenceRockstroh JK, 2017, ANTIVIR THER, V22, P225, DOI 10.3851/IMP3108eng
hcfmusp.relation.referenceRockstroh JK, 2014, CURR OPIN HIV AIDS, V9, P365, DOI 10.1097/COH.0000000000000064eng
hcfmusp.relation.referenceRoncero C, 2018, EXPERT REV CLIN PHAR, V11, P999, DOI 10.1080/17512433.2018.1519392eng
hcfmusp.relation.referenceSANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2eng
hcfmusp.relation.referenceSikavi C, 2018, HEPATOLOGY, V67, P847, DOI 10.1002/hep.29642eng
hcfmusp.relation.referenceSmith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8eng
hcfmusp.relation.referenceSmolders E, 2018, HIV MED, V19, P216, DOI 10.1111/hiv.12570eng
hcfmusp.relation.referenceSogni P, 2016, CLIN INFECT DIS, V63, P763, DOI 10.1093/cid/ciw379eng
hcfmusp.relation.referenceSoto B, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80001-3eng
hcfmusp.relation.referenceStepanova M, 2017, CLIN LIVER DIS, V21, P579, DOI 10.1016/j.cld.2017.03.012eng
hcfmusp.relation.referenceSterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178eng
hcfmusp.relation.referenceSulkowski MS, 2014, SEMIN LIVER DIS, V34, P72, DOI 10.1055/s-0034-1371012eng
hcfmusp.relation.referenceVogel M, 2009, EUR J MED RES, V14, P507, DOI 10.1186/2047-783X-14-12-507eng
hcfmusp.relation.referenceWebster DP, 2015, LANCET, V385, P1124, DOI 10.1016/S0140-6736(14)62401-6eng
hcfmusp.relation.referenceWorld Health Organization, 2016, GUID SCREEN CAR TREAeng
hcfmusp.relation.referenceWorld Health Organization, 2017, GLOB HEP REPeng
hcfmusp.relation.referenceWyles DL, 2015, NEW ENGL J MED, V373, P714, DOI 10.1056/NEJMoa1503153eng
hcfmusp.relation.referenceWyles DL, 2017, CURR HIV-AIDS REP, V14, P229, DOI 10.1007/s11904-017-0369-5eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication0bb3fa08-3c36-4891-a92b-cbf13dd0d1ed
relation.isAuthorOfPublication0ada2eb1-5ac2-4e40-b4e2-6af14f33268b
relation.isAuthorOfPublicationa9324386-13b6-4aae-8f0c-8273588275c3
relation.isAuthorOfPublication982a41ad-b2bf-40bb-8f9f-0cf5e2bafd95
relation.isAuthorOfPublication1b8dfcc8-906a-4df2-91c2-3c7c7b08f46d
relation.isAuthorOfPublication4ec4044d-75d1-4d30-8176-efd04b22c8d6
relation.isAuthorOfPublication.latestForDiscovery0bb3fa08-3c36-4891-a92b-cbf13dd0d1ed
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_MACHADO_Effectiveness_of_directacting_antivirals_for_hepatitis_C_virus_2020.PDF.pdf
Tamanho:
307.95 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/01
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/07
Carregar mais